drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Allogeneic, gene-edited chimeric antigen receptor T lymphocytes engineered to target CD19 on B-lineage cells; administered as a single IV infusion after lymphodepletion to deplete CD19+ B cells/plasmablasts and reduce autoantibody production.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, gene-edited T cells engineered with an anti-CD19 chimeric antigen receptor bind CD19 on B-lineage cells. CAR engagement activates T-cell cytotoxic pathways (e.g., perforin/granzyme, Fas–FasL), leading to targeted depletion of CD19+ B cells and plasmablasts, thereby reducing autoantibody production and modulating humoral immunity.
drug_name
Anti-CD19 UCAR-T cells
nct_id_drug_ref
NCT06686524